Oral cavity squamous cell carcinoma

This phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…

This study compares standard radiation plus cisplatin against two experimental approaches: radiation with docetaxel and cetuximab, or radiation with cisplatin and the immunotherapy drug atezolizumab. About 613 patients with high-risk stage III-IV head and neck cancer will partici…

This phase I trial is testing whether a combination of three treatments — an experimental drug called elimusertib, precise radiation therapy, and the immunotherapy pembrolizumab — can shrink or stabilize recurrent head and neck cancer that cannot be removed by surgery. The study …

This early-phase trial tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation in people with advanced head and neck cancer that has spread to nearby tissues. The main goals are to find the safest dose and to see what side effects occ…

This phase 2 trial tests a weekly combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy pembrolizumab in 31 patients with metastatic head and neck cancer who cannot receive the standard drug 5-fluorouracil. The goal is to see if this regimen sh…

This phase II trial is testing whether combining the immunotherapy drug cemiplimab with low doses of two chemotherapy drugs (paclitaxel and carboplatin) can shrink tumors in people with head and neck cancer that has come back or spread. The study includes 46 participants who have…

This early-phase trial is testing whether adding the drug peposertib to standard radiation therapy is safe and effective for people with advanced head and neck cancer who cannot take the chemotherapy drug cisplatin. The study involves 21 participants and aims to find the best dos…

This study tests a three-drug combination (sorafenib, carboplatin, and paclitaxel) in 48 people with head and neck cancer that has spread or returned. The goal is to see how well the treatment shrinks tumors and delays cancer growth. Participants must have a confirmed diagnosis a…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This study tests whether giving two immunotherapy drugs (tiragolumab and atezolizumab) before and after standard surgery and chemoradiation can help control advanced oral cancer. It includes 29 adults with newly diagnosed, stage 3-4 oral cavity squamous cell carcinoma that has a …

This study tests whether adding the experimental drug ipatasertib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with head and neck cancer that has returned or spread. About 52 adults with incurable, advanced squamous cell carcinoma w…

This study tests a shorter, more intense course of radiation therapy (hypofractionated IMRT) given after surgery for head and neck cancer. The goal is to see if it is safe and if it can help patients maintain better swallowing function compared to the standard longer radiation sc…

This study tests two immunotherapy drugs, nivolumab and ipilimumab, given before surgery to people with oral cavity squamous cell carcinoma. The goal is to see if these drugs can shrink tumors and are safe to use. About 30 adults with tumors larger than 2 cm or lymph node involve…

This study tests whether adding two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can help control locally advanced head and neck cancer. About 45 adults with this cancer will receive the drug combination. The main goal is to see if this approach imp…

This study tests two drugs, pembrolizumab and cabozantinib, in 36 people with head and neck cancer that has returned or spread and cannot be surgically removed. The goal is to see if the combination shrinks tumors and delays cancer growth. Participants receive both drugs intraven…

This study tests an oral drug called APG-157 given before standard treatment (surgery or radiation) for people with newly diagnosed head and neck cancer. The goal is to see if the drug can shrink tumors and improve outcomes. About 24 adults with early to advanced stage cancer wil…

This phase 2 trial tests whether adding the immunotherapy drug tirellizumab plus chemotherapy before standard surgery can improve outcomes for people with early oral squamous cell carcinoma. Sixty participants will be randomly assigned to either the drug combo plus surgery or sur…

This study tests whether the immunotherapy drug pembrolizumab (Keytruda) combined with radiation works better than the standard chemotherapy drug cisplatin with radiation for patients with a certain type of head and neck cancer (p16-positive). About 126 adults with advanced or in…

This study tests a fluorescent dye called PARPi-FL that may make oral cancer cells glow during an endoscopic exam. About 23 people with oral squamous cell carcinoma will gargle the dye before surgery, and doctors will check for safety and how well the dye highlights tumors. It is…

This study tests a new dye, called cRGDY-PEG-Cy5.5-C dots, to help surgeons see cancer in lymph nodes during head and neck melanoma surgery. About 67 people will receive the dye injection around their tumor before or during surgery. The dye is not a treatment, but may improve how…

This study investigates whether a painless fluorescent light exam can help find early warning signs of oral cancer in adults. Participants complete a health questionnaire and receive a standard oral exam plus a fluorescence scan. The goal is to see if this simple, non-invasive to…

This trial tests Gelclair, a mouth rinse that forms a protective coating over the mouth's lining, to see if it eases the painful mouth sores (oral mucositis) caused by radiation therapy for head and neck cancer. The study enrolls adults with squamous cell carcinoma who will recei…

This phase 2 trial tests whether the drug RRx-001 can prevent severe oral mucositis (painful mouth sores) in 216 patients with head and neck cancer receiving standard chemoradiation. Patients are randomly assigned to receive RRx-001 or a placebo alongside their usual treatment. T…

This study compares two pain management strategies for adults with oral cancer who have moderate to severe pain. One group receives the opioid tramadol, while the other gets a combination of pregabalin and naproxen sodium. Over 7 days, researchers measure pain reduction, side eff…

This study tests whether a remote rehabilitation app can improve shoulder and neck recovery in oral cancer patients who had neck dissection surgery. 80 patients are randomly assigned to either standard home exercise materials or the app, which provides daily reminders and lets pa…

This study talks to people living with HIV from diverse backgrounds to learn what helps or hinders them from getting oral health care and cancer prevention. Researchers will hold focus groups and use questionnaires to understand barriers and gather ideas for improvement. The goal…

This study investigates whether head and neck cancers caused by HPV have different genetic profiles compared to those linked to alcohol and tobacco use. By analyzing tumor biopsies, researchers aim to identify genetic markers that could predict how well a patient responds to chem…

This study looks at whether testing the surgical wound for leftover tumor DNA can help predict if oral cancer will come back. Researchers will check for this DNA in 31 patients after their tumor is removed. The goal is to see if this test gives useful information beyond standard …